$181.00 - $181.00
Biotin-Neurokinin A is an N-terminally biotinylated derivative of full-length Neurokinin A. The construct retains the complete HKTDSFVGLM-NH₂ sequence while adding a biotin handle for affinity capture and detection.
Product Information
| Property | Specification |
|---|---|
| Product Name | Biotin-Neurokinin A |
| Catalog No. | AS2631 |
| Sequence | Biotin-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH₂ |
| One-Letter Sequence | Biotin-HKTDSFVGLM-NH₂ |
| Molecular Formula | C60H94N16O16S2 |
| Molecular Weight | Approximately 1359.64 Da |
| Modification | N-terminal biotin |
| Reference Receptor | NK2R |
A Capture-Compatible Full-Length NKA Construct
The entire endogenous NKA backbone remains present, including the C-terminal DSFVGLM-NH₂ tachykinin pharmacophore. N-terminal biotin introduces a high-affinity interaction site for streptavidin-based assay formats.
Useful for Surface and Interaction Studies
Potential applications include immobilized ligand experiments, affinity capture, receptor-interaction workflows and development of analytical tachykinin assays.
Surface immobilization may alter ligand orientation or apparent kinetics, so soluble native NKA remains an appropriate reference for quantitative pharmacology.
Biotinylation Requires Functional Validation
The native His1 N-terminus is chemically modified in this construct. We therefore recommend measuring signaling or binding behavior directly rather than stating that biotinylation preserves native NKA activity.
Alternative label positions or linker-containing constructs can be evaluated through Chemical Peptide Synthesis.
Frequently Asked Questions
Does the construct retain all 10 NKA residues?
Yes. Biotin is added before the native His1 residue.
Can biotinylated and native NKA be assumed to have identical potency?
No. Quantitative activity should be validated experimentally.